Conditions: Bone Loss
Keywords: spinal cord injury osteoporosis bone loss zoledronic acid bisphosphonate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 17
Healthy volunteers: no

Brief summary:
This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture. The goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this population. Outcome measures will include bone density determinations over a one year period.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: zoledronic acid intervention 2: placebo
Intervention descriptions: intervention 1: zoledronic acid, 5mg, iv intervention 2: iv

Protocol document: